ARID1A and neoplasm: We found that, compared with vehicle treatment, VX-970 had no effect on ARID1A+/+ tumours (P=0.45, ANOVA, Fig. 3b) but significantly inhibited the growth of ARID1A−/− tumours (P=0.024, ANOVA, Fig. 3b).